Tykerb and Lower respiratory tract infection - a phase IV clinical study of FDA data

Summary:

Lower respiratory tract infection is reported only by a few people who take Tykerb.

The phase IV clinical study analyzes which people take Tykerb and have Lower respiratory tract infection. It is created by eHealthMe based on reports of 11,953 people who have side effects while taking Tykerb from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

11,953 people reported to have side effects when taking Tykerb.
Among them, 4 people (0.03%) have Lower respiratory tract infection.

What is Tykerb?

Tykerb has active ingredients of lapatinib ditosylate. It is often used in breast cancer. eHealthMe is studying from 11,998 Tykerb users for its effectiveness, alternative drugs and more.

What is Lower respiratory tract infection?

Lower respiratory tract infection is found to be associated with 1,731 drugs and 1,064 conditions by eHealthMe.

Number of Tykerb and Lower respiratory tract infection reports submitted per year:

Could Tykerb cause Lower respiratory tract infection?

Time on Tykerb when people have Lower respiratory tract infection *:

Gender of people who have Lower respiratory tract infection when taking Tykerb *:

female: 75 %
male: 25 %

Age of people who have Lower respiratory tract infection when taking Tykerb *:

Common drugs people take besides Tykerb *:

Common side effects people have besides Lower respiratory tract infection *:

Oral Pain: 2 people, 50.00%
Device Related Infection: 2 people, 50.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 25.00%
Nausea (feeling of having an urge to vomit): 1 person, 25.00%
Gastrointestinal Anastomotic Leak (breakdown at the site of a post-surgical closure of a stomach and intestine): 1 person, 25.00%
Drug Ineffective: 1 person, 25.00%
Diarrhea: 1 person, 25.00%
Breathing Difficulty: 1 person, 25.00%

Common conditions people have *:

Asthma: 1 person, 25.00%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tykerb and have Lower respiratory tract infection?

Check whether Lower respiratory tract infection is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Lower respiratory tract infection and when was it recovered:

Lower respiratory tract infection in Tykerb

Expand to all the drugs that have ingredients of lapatinib ditosylate:

Lower respiratory tract infection and drugs with ingredients of lapatinib ditosylate

Alternative drugs to, pros and cons of Tykerb:

Tykerb (11,998 reports)

Common Tykerb side effects:

Browse all side effects of Tykerb:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Lower respiratory tract infection treatments and more:

Lower respiratory tract infection (49,239 reports)

COVID vaccines that are related to Lower respiratory tract infection:

Common drugs associated with Lower respiratory tract infection:

All the drugs that are associated with Lower respiratory tract infection:

Lower respiratory tract infection (1,731 drugs)

Common conditions associated with Lower respiratory tract infection:

Rheumatoid arthritis: 10,422 reports
Asthma: 4,091 reports
Psoriasis: 2,611 reports
Crohn's disease: 1,675 reports
Schizophrenia: 1,623 reports

All the conditions that are associated with Lower respiratory tract infection:

Lower respiratory tract infection (1,064 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lapatinib ditosylate (the active ingredients of Tykerb) and Tykerb (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.